Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1
  • Main
  • Сlinical Trials
    • Completed phase I/IIa clinical trial
    • Case studies
    • Ex-US Clinical Trials
    • US clinical trials
  • Dogs & Cats
    • Comparative Medicine and Veterinary Research
  • Elenagen
    • Elenagen is a Plasmid (Circular DNA) Encoding Gene P62/SQSTM1
    • Elenagen Reduces/Reverts Tumor Grade
    • Elenagen Changes Tumor Microenvironment
    • Elenagen Downregulates Chronic Inflammation
    • Elenagen Enhances Anti-Tumoral Immune Response
  • IP
  • Publications
  • Investors
    • One-pager
    • Slide presentation
  • Team
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Careers
  • News
    • Company news
    • In the news
  • Legal
Hormone-Resistant Prostate and Breast Cancers Added to Clinical Study Based on Encouraging Preliminary Results
August 11, 2021
OncologyTube interviews Dr. Alex Shneider of CureLab Oncology and Prof. Sergei Krasny
November 11, 2021
September 16, 2021

CureLab Oncology Presents at 2021 ESMO Congress

The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy
esmo2021

BOSTON – September 16, 2021: CureLab Oncology’s a clinical-stage biotech company, is presenting at this year’s European Society for Medical Oncology. Two reports were accepted and are featured as e-posters in the oncology/PRO educational portal for oncologists.

The reports describe findings resulting from CureLab’s clinical trials of Elenagen™, an experimental DNA therapy, that are currently underway at N.N. Alexandrov National Cancer Centre of Belarus under the direction of a team led by Deputy Director Professor Sergei Krasny, MD, DSc.

The reports are available online:

  1. Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients
  2. Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer

About Elenagen

CureLab’s lead investigational compound is code-named Elenagen, an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In animal studies and Phase I/II human trials conducted ex-US, Elenagen has shown promise in reversing tumor grade, changing the tumor microenvironment, and enhancing the anti-cancer effects of chemotherapy. Experimental results indicate a mitigation of chronic inflammation and stimulation of an immune response to the tumor.

About CureLab Oncology

CureLab Oncology Inc. is a pre-IPO, clinical-stage immuno-oncology biotech company headquartered in the greater Boston area. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelaboncology.com.

Media contact:

Tim Cox, ZingPR, tim@zingpr.com

Share

Related posts

November 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison


Read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

  • The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
  • The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
  • We are now preparing Phase II Clinical Trials within the US.

Contact us

E-mail:

info@curelab.com,

Call us:

1-609-841-1201

177 HUNTINGTON
AVE FL 17
BOSTON MA 02115-3156
© 2020 CureLab Oncology.